High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma CellsLindy Vernooij(Princess Máxima Center), M. Emmy M. Dolman(University of Amsterdam)Molecular Cancer TherapeuticsApril 13, 202110.1158/1535-7163.mct-20-0666Cited by 18SaveCiteExport RISWatch citationsRelated PapersHigh efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition|Oncotarget|2016|61